LENZ Therapeutics and Lotus Pharmaceutical have partnered to commercialize LNZ100 for presbyopia in Korea and Southeast Asia.
Quiver AI Summary
LENZ Therapeutics, Inc. and Lotus Pharmaceutical Co., Ltd. have entered into an exclusive licensing and commercialization agreement for LNZ100, an aceclidine-based eye drop intended to treat presbyopia, to be marketed in South Korea and select Southeast Asian nations. Under the agreement, LENZ could earn up to $125 million through milestone payments and will receive royalties on net sales. Lotus aims to leverage its commercial strength and experience to bring LNZ100 to this region, which has over 100 million individuals affected by presbyopia. LENZ announced in October 2024 that the FDA has accepted the New Drug Application for LNZ100, with a target action date set for August 8, 2025.
Potential Positives
- LENZ Therapeutics will receive up to $125 million in upfront, regulatory, and commercial milestone payments, along with tiered double-digit royalties on future net sales of LNZ100.
- The partnership with Lotus Pharmaceutical, a well-established company with a proven track record and extensive commercial infrastructure, enhances the likelihood of successful market entry for LNZ100 in Southeast Asia.
- LNZ100 addresses a significant global health issue, impacting an estimated 1.8 billion people, positioning LENZ Therapeutics as a key player in a large and underserved market.
- The FDA's acceptance of the NDA for LNZ100 indicates progress towards commercialization, with a target action date set for August 8, 2025, which could pave the way for increased revenue opportunities.
Potential Negatives
- LENZ Therapeutics has entered into an exclusive licensing agreement with Lotus Pharmaceutical, which may limit LENZ's direct control over the commercialization and marketing of LNZ100 in the specified regions.
- As a pre-commercial-stage company, LENZ depends heavily on the success of LNZ100, which still requires FDA approval, creating uncertainty about future revenue streams.
- The press release does not disclose any contingency plans or risk management strategies for potential delays or issues in obtaining regulatory approvals for LNZ100, which may signal vulnerability in their business strategy.
FAQ
What is the agreement between LENZ Therapeutics and Lotus Pharmaceutical?
LENZ Therapeutics and Lotus Pharmaceutical have established an exclusive license agreement for Lotus to commercialize LNZ100 for presbyopia in specific regions.
What is LNZ100 and its purpose?
LNZ100 is an aceclidine-based eye drop designed to improve near vision in individuals suffering from presbyopia.
When is the FDA action date for LNZ100?
The FDA has set a Prescription Drug User Fee Act target action date of August 8, 2025, for LNZ100.
How much will LENZ receive from Lotus for the commercialization rights?
LENZ will receive up to $125 million in upfront and milestone payments, plus tiered royalties on future net sales.
Which regions will Lotus be commercializing LNZ100?
Lotus will commercialize LNZ100 in the Republic of Korea and several Southeast Asian countries, including Thailand and Singapore.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LENZ Hedge Fund Activity
We have seen 53 institutional investors add shares of $LENZ stock to their portfolio, and 35 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 770,455 shares (+inf%) to their portfolio in Q4 2024, for an estimated $22,243,035
- PRICE T ROWE ASSOCIATES INC /MD/ added 374,326 shares (+83.4%) to their portfolio in Q4 2024, for an estimated $10,806,791
- ECOR1 CAPITAL, LLC removed 346,772 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $10,011,307
- SAMSARA BIOCAPITAL, LLC removed 221,492 shares (-18.3%) from their portfolio in Q4 2024, for an estimated $6,394,474
- STATE STREET CORP added 205,162 shares (+71.0%) to their portfolio in Q4 2024, for an estimated $5,923,026
- PARKMAN HEALTHCARE PARTNERS LLC removed 139,357 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $4,023,236
- SCHONFELD STRATEGIC ADVISORS LLC removed 107,300 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $3,097,751
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia. LENZ Therapeutics is a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia. Lotus is a leading global pharmaceutical company focused on commercializing novel pharmaceuticals to provide patients with better, safer and more accessible medicines.
Under the terms of the licensing and commercialization agreement, LENZ will receive up to $125 million in upfront, regulatory and commercial milestone payments, as well as tiered, double-digit royalties on future net sales. Lotus will have exclusive development, manufacturing, registration and commercialization rights for LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia, including Thailand, Philippines, Vietnam, Malaysia, Brunei, Indonesia and Singapore.
“We are very excited to partner with the team at Lotus to bring LNZ100 to Southeast Asia, given their proven track record for successful global partnerships, robust commercial infrastructure in the region and six consecutive years of double-digit revenue growth, now exceeding USD $500 million. Upon approval, we look forward to the Lotus team bringing LNZ100 to this important and commercially attractive region,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “We are committed to partnering with leading commercial pharmaceutical companies ex-US, providing access to LNZ100 for patients worldwide.”
Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical, commented: “We are very pleased to be the trusted partner of LENZ to help bring such a transformative product that will significantly enhance the lives of more than 100 million people in this region who are currently impacted by presbyopia. Our commitment to excellence drives us to diligently pursue the necessary regulatory approvals and eventually leverage our extensive network of channels to ensure seamless access to this life-altering solution. Our dedication to innovation and safety remains unwavering as we continuously strive to provide better and safer pharmaceuticals to the markets that we serve.”
In October 2024, LENZ announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia, a condition that impacts an estimated 1.8 billion people globally and 128 million people in the United States. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100, and noted it is not planning to hold an Advisory Committee Meeting to discuss this application.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit:
LENZ-Tx.com
.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Contacts: | |
Dan Chevallard | Yu-ying Yang, Associate Director, Corporate Communications |
LENZ Therapeutics | Lotus Pharmaceutical Co., Ltd. |
[email protected] | [email protected] |